Business Wire

ESI-GROUP

22.9.2021 14:26:12 CEST | Business Wire | Press release

Share
ESI Group: EMPHYSIS – The Missing Link Between Digital Simulation and Embedded Software

Regulatory News:

ESI Group (Paris:ESI):

The research project EMPHYSIS led by Bosch has delivered the new “eFMI standard” for model exchange to accelerate the model-based development of embedded software. On the 15th of September, this international collaborative project gathering 25 industrial and academic partners from different fields (like automotive and information technologies) situated in Belgium, Canada, France, Germany, and Sweden received the ITEA Award of Excellence for this unique achievement.

Better code with less effort through “eFMI” - the new model-exchange standard for embedded devices

When developing a new function, many engineers learn the hard way that their outstanding knowledge about the physics of their products is not enough by far to develop a function for an embedded target, due to the demanding requirements of safety-critical software, weak CPU magnitude and less memory than expected. While this might result in a never-to-be-realised excellent initial idea of operating and controlling their product in a much smarter way, at the same time it reveals the need for a link between digital simulation of physical processes and embedded software.

The aim of the EMPHYSIS project (Embedded Systems with Physical Models in the Production Code Software), led by Bosch, was to jointly come up with a new open standard that lays the foundation to develop new innovative tools. This that allows model-based functions to be realized directly in embedded software with better code and less effort. For this purpose, the project carried forward the idea of the very successful Functional Mock-up Interface (FMI) model exchange standard for simulation to develop FMI for embedded systems - the new “eFMI standard”. This enables a wide variety of advanced model-based approaches for control and diagnosis, such as solving a set of differential equations to compute a signal instead of measuring it via a sensor. By allowing a hardware sensor to be replaced with a piece of software, we significantly reduce the total cost.

« The EMPHYSIS project has achieved several outstanding results such as the automatic generation of efficient code for embedded devices. It shows the power of collaborative research projects to drive the adoption of a new standard and to generate significant productivity gains for the industry. »

– Jean-François Lavignon, ITEA Vice-chairman

The technical deep dive and benefits

Technically speaking, eFMI is innovative in that it provides a target-independent intermediate format defined by an entirely new language, the Guarded Algorithmic Language for Embedded Control: GALEC. This new programming language is able to guarantee that an algorithm described in this language can be translated into code that has:

  • static worst-case execution time;
  • static a-priori known memory demand; and
  • a statically proven absence of illegal memory access.

In other words: code that satisfies the hard requirements of automotive safety-critical embedded software, which also makes it applicable to many more, less restricted domains like robotics, industrial applications and consumer goods.

With eFMI and GALEC it is now possible to capture the computational essence of a model in a target-independent form that is a solid foundation for any code generator to produce highly optimised code for arbitrary runtime environments and software architectures. All this is cast into a traceable, extendable and verifiable container architecture that goes far beyond a simple exchange format.

The eFMI workflow allows developers to model a system on a higher level of abstraction, starting with a reusable, high-level, component-oriented and physically structured model. The tooling kit then automatically transforms this into a solution which can be better integrated into software.

The main benefits of this solution and the associated eFMI workflow are:

  • accelerating development time;
  • better use of domain experts by separating the concerns of physical modelling and embedded implementation;
  • overcoming vendor lock-in through eFMI being published as an open standard on GitHub; and
  • enabling new ways of OEM supplier collaborations.

Continuous success

An OEM Advisory Board has been established to gather additional requirements, input and use-cases and further disseminate the project’s results, helping to secure uptake and future innovations in new domains.

On 22 March 2021, right after the project’s end, the non-profit Modelica Association officially approved a new project under its umbrella to further develop, standardize and promote eFMI. With Robert Bosch GmbH, Dassault Systèmes, DLR Institute of System Dynamics and Control, dSPACE, ESI Group, ETAS GmbH and Modelon AB as initial members of the steering committee and Mercedes-Benz AG having joined recently, the first official release of eFMI 1.0 is targeted within 2021. Having developed 14 tools within EMPHYSIS, eFMI already has a broad foundation even before its official release.

« What makes us proud as a team is the fact that this success has been recognized not only by our business partners and the OEM Advisory Board representing the voice of the customer, but also by the ITEA organization.»

– Oliver Lenord, Research Engineer at the Model-based Systems Engineering department at Robert Bosch

For society as a whole, EMPHYSIS’ better software translates into safer and more efficient vehicles which are able to keep pace with customer demands and help tackle climate issues in the longer term. For the time being, however, the project’s message is clear: by taking full advantage of an equation-based, component-oriented modelling language with a good library, 90% gains can be made in productivity of model-based function development.

EMPHYSIS project partners

Belgium

  • Dana Belgium
  • Siemens Industry Software NV
  • University of Antwerp NEXOR

Canada

  • Maplesoft

France

  • CEA
  • Dassault Systemes SE
  • FH Electronics
  • Institut Polytechnique de Grenoble
  • OSE Engineering
  • Renault SAS
  • Siemens Industry Software SAS
  • SOBEN

Germany

  • AbsInt Angewandte Informatik GmbH
  • Deutsches Zentrum für Luft- und Raumfahrt (DLR) System Dynamics and Control
  • dSPACE GmbH
  • Elektronische Fahrwerksysteme GmbH
  • ESI ITI GmbH, part of ESI Group
  • ETAS GmbH
  • PIKETEC
  • Robert Bosch GmbH

Sweden

  • Dassault Systèmes AB
  • Linköping University
  • Modelon AB
  • RISE - Research institutes of Sweden SICS East
  • Volvo Personvagnar AB

About ITEA

ITEA is the Eureka Cluster for software innovation, enabling a large international community to collaborate in funded projects that turn innovative ideas into new businesses, jobs, economic growth and benefits for society. https://itea4.org

About ESI Group

Founded in 1973, ESI Group envisions a world where Industry commits to bold outcomes, addressing high stakes concerns - environmental impact, safety & comfort for consumers and workers, adaptable and sustainable business models. ESI provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise to allow industries to make the right decisions at the right time, while managing their complexity. Acting principally in automotive & land transportation, aerospace, defense & naval, energy and heavy industry, ESI is present in more than 20 countries, employs 1200 people around the world and reported 2020 sales of €132.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.

For further information: https://www.esi-group.com/fr .

Follow ESI

http://www.esi-group.com/linkedin
http://www.esi-group.com/facebook
http://www.esi-group.com/twitter
http://www.esi-group.com/youtube

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye